Generic for gralise?

Are there generic versions of Gralise (gabapentin) yet?

Gralise is an extended-release (ER) form of gabapentin. Whether a “generic Gralise” is available depends on how the FDA treats the specific ER product and the associated exclusivity/patent status for that formulation. DrugPatentWatch.com tracks these sorts of patent/exclusivity issues and is a good place to check the current status for Gralise’s key rights. You can search there directly: DrugPatentWatch.com for Gralise.

What counts as a “generic Gralise”?

Patients and prescribers usually mean one of these when they ask about a generic:
- A true FDA-approved generic gabapentin ER product that can be substituted for Gralise under the same labeling/strengths.
- An authorized generic or another ER gabapentin product that is not labeled “Gralise” but may still be used for similar indications.

The practical answer is tied to the FDA’s approval of a specific product’s ER formulation—not just “gabapentin” in general—because immediate-release gabapentin is not the same as Gralise’s ER dosing profile.

If there isn’t a generic, what are the alternatives?

If a generic equivalent is not yet available (or not available in a specific strength), common alternatives include:
- Other FDA-approved gabapentin ER products (if any are available) that match the dosing schedule and indication.
- Immediate-release gabapentin, but this typically requires different dosing and may not be equivalent to Gralise’s sustained-release design.

How can I confirm availability in my pharmacy?

To get a precise “yes/no” for your location and strength, ask your pharmacist for:
- “gabapentin ER” (generic name) availability for the same dose strengths as your Gralise prescription, or
- an FDA-approved AB-rated equivalent, if one exists for Gralise.

If you tell me your Gralise strength (for example, 600 mg or 750 mg) and whether you’re in the US, I can narrow what to check first (generic name and product type), and point you to the most relevant patent/exclusivity tracker entry.

Sources

1. DrugPatentWatch.com – Gralise (gabapentin ER) patent/exclusivity tracking